Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide in patients with chronic hepatitis B and risk factors for TDF use

被引：0

作者：

Gane, E. ^{[1
]}

Seto, W. K. ^{[2
]}

Janssen, H. ^{[3
]}

Caruntu, F. A. ^{[4
]}

Kim, H. J. ^{[5
]}

Abdurakhmanov, D. ^{[6
]}

Nishiguchi, S. ^{[7
]}

Andrzej, H. ^{[8
]}

Bae, H. ^{[9
]}

Mo, S. ^{[10
]}

Suri, V. ^{[10
]}

Gaggar, A. ^{[10
]}

Flaherty, J. F. ^{[10
]}

Kao, J-H ^{[11
]}

Brunetto, M. ^{[12
]}

Buti Ferret, M. ^{[13
]}

机构：

[1] Auckland Clin Studies, Auckland, New Zealand

[2] Queen Mary Hosp, Hong Kong, Peoples R China

[3] Toronto Gen Hosp, Toronto, ON, Canada

[4] Natl Inst Infect Dis Matei Bals, Infect Dis, Bucharest, Romania

[5] Chung Ang Hosp, Seoul, South Korea

[6] Sechenov First Moscow State Med Univ, Moscow, Russia

[7] Hyogo Coll Med Hosp, Nishinomiya, Hyogo, Japan

[8] SP ZOZ Wojewodzki Szpital Zakazny Warszawie, Warsaw, Poland

[9] Asian Pacific Liver Ctr, Los Angeles, CA USA

[10] Gilead Sci Inc, Foster City, CA USA

[11] Natl Taiwan Univ, Taipei, Taiwan

[12] Azienda Osped Univ Pisana, UO Epatol, Pisa, Italy

[13] Hosp Univ Vall dHebron, Barcelona, Spain

来源：

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | 2018年 / 33卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：42 / 43

页数：2

共 50 条

[1] Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use
Janssen, H.
Gane, E.
Seto, W-K
Caruntu, F. A.
Kim, H. J.
Abdurakhmanov, D.
Nishiguchi, S.
Horban, A.
Bae, H.
Mo, S.
Suri, V.
Gaggar, A.
Flaherty, J.
Kao, J-H
Brunetto, M.
Ferret, M. B.
JOURNAL OF VIRAL HEPATITIS, 2018, 25 : 27 - 27
[2] Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use
Gane, Edward
Seto, Wai Kay
Janssen, Harry L. A.
Caruntu, Florin A.
Kim, Hyung Joon
Abdurakhmanov, Dzhamal
Nishiguchi, Shuhei
Horban, Andrzej
Bae, Ho
Flaherty, John F.
Gaggar, Anuj
Suri, Vithika
Oberle, Corinna
Mo, Shuyuan
Subramanian, G. Mani
Kao, Jia-Horng
Brunetto, Maurizia
Buti, Maria
SWISS MEDICAL WEEKLY, 2018, 148 : 26S - 26S
[3] 1 YEAR SAFETY AND EFFICACY DATA IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TENOFOVIR DISOPROXIL FUMARATE (TDF) AFTER SWITCHING FROM TDF TO TENOFOVIR ALAFENAMIDE (TAF)
Pan, Calvin Q.
Gane, Edward
Seto, Wai-Kay
Janssen, Harry L.
Caruntu, Florin
Kim, Hyung Joon
Abdurakhmanov, Dzhamal
Nishiguchi, Shuhei
Bae, Ho
Mo, Shuyuan
Suri, Vithika
Gaggar, Anuj
Flaherty, John F.
Kao, Jia-Horng
Brunetto, Maurizia Rossana
Buti, Maria
GASTROENTEROLOGY, 2018, 154 (06) : S1132 - S1133
[4] SAFETY AND EFFICACY AT 48 WEEKS AFTER SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TENOFOVIR ALAFENAMIDE (TAF) IN CHRONIC HBV PATIENTS WITH RISK FACTORS FOR TDF USE
Buti, Maria
Lampertico, Pietro
Lim, Young-Suk
Agarwal, Kosh
Fung, Scott K.
Tsang, Owen
Elkhashab, Magdy
Kao, Jia-Horng
Luis Calleja, Jose
Khalili, Mandana
Ravendhran, Natarajan
Tan, Susanna
Flaherty, John F.
Gaggar, Anuj
Lau, Audrey H.
Wu, George
Hann, Hie-Won L.
Pan, Calvin
Kim, Hyung Joon
Kennedy, Patrick T. F.
Chan, Henry Lik Yuen
HEPATOLOGY, 2019, 70 : 301A - 301A
[5] Safety and efficacy at 1 year after switching from Tenofovir Disoproxil Fumurate to Tenofovir Alafenamide in chronic HBV patients with risk factors for TDF use
Gane, E.
Seto, W-K.
Janssen, H.
Caruntu, F. A.
Kim, H. J.
Abdurakhmanov, D.
Nishiguchi, S.
Andrzej, H.
Bae, H.
Mo, S.
Suri, V.
Gaggar, A.
Flaherty, J. F.
Kao, J-H.
Brunetto, M.
Ferret, M. B.
JOURNAL OF HEPATOLOGY, 2018, 68 : S87 - S87
[6] 48-WEEK SAFETY AND EFFICACY OF SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HBV ASIAN PATIENTS WITH TDF RISK FACTORS (RF)
Ahn, Sang Hoon
Kao, Jia-Horng
Hann, Hie-Won
Scott, Fung
Trinh, Huy
Nguyen, Tuan Trong
Paik, Seung Woon
Gaggar, Anuj
Flaherty, John
Yee, Leland
Jump, Belinda
Sethi, Shalini
Wu, George
Chan, Carol Yee Kwan
GUT, 2020, 69 : A73 - A74
[7] From Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF): Perspectives in Pediatric Patients with Chronic Hepatitis B
Rodrigo, Minna
Hartley, Christopher
Wasuwanich, Paul
Van, Trung
Karnsakul, Wikrom
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2024, 22 (12) : 1099 - 1106
[8] BONE AND RENAL SAFETY ARE IMPROVED IN CHRONIC HBV PATIENTS 1 YEAR AFTER SWITCHING TO TENOFOVIR ALAFENAMIDE (TAF) FROM TENOFOVIR DISOPROXIL FUMARATE (TDF)
Chan, Henry Lik Yuen
Seto, Wai Kay
Buti, Maria
Izumi, Namiki
Lim, Young-Suk
Kao, Jia-Horng
Streinu-Cercel, Adrian
Nurmukhametova, Elena
Ma, Xiaoli
Tabak, Fehmi
Jablkowski, Maciej
Suri, Vithika
Flaherty, John
Lau, Audrey
Gaggar, Anuj
Mo, Shuyuan
Chowdhury, Abhijit
Fung, Scott
Chuang, Wan-Long
Gane, Edward
GUT, 2019, 68 : A141 - A142
[9] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) AT 96 WEEKS IN CHRONIC HBV (CHB) PATIENTS WITH RISK FACTORS FOR USE OF TENOFOVIR DISOPROXIL FUMARATE (TDF)
Chan, Henry Lik-Yuen
Buti, Maria
Flisiak, Robert
Ryder, Stephen
Streinu-Cercel, Adrian
Flaherty, John F.
Gaggar, Anuj
Mo, Shuyuan
Subramanian, G. Mani
Zoulim, Fabrian
Andreone, Pietro
Marcellin, Patrick
GUT, 2018, 67 : A97 - A97
[10] Bone and Renal Safety Are Improved in Chronic HBV Patients 1 Year after Switching to Tenofovir Alafenamide (TAF) from Tenofovir Disoproxil Fumarate (TDF)
Seto, Wai Kay Walter
Buti, Maria
Izumi, Namiki
Lim, Young-Suk
Kao, Jia-Horng
Streinu-Cercel, Adrian
Nurmukhametova, Elena
Ma, Xiaoli
Tabak, Fehmi
Jablkowski, Maciej
Suri, Vithika
Flaherty, John F.
Lau, Audrey H.
Gaggar, Anuj
Mo, Shuyuan
Chowdhury, Abhijit
Fung, Scott K.
Chuang, Wan-Long
Gane, Edward J.
HEPATOLOGY, 2018, 68 : 240A - 241A

← 1 2 3 4 5 →